Literature DB >> 20670675

Mechanisms of L-DOPA-induced cytotoxicity in rat adrenal pheochromocytoma cells: implication of oxidative stress-related kinases and cyclic AMP.

C M Jin1, Y J Yang, H S Huang, M Kai, M K Lee.   

Abstract

L-DOPA therapy for Parkinson's disease has a double-edge effect on nigrostriatal dopaminergic neurons: L-DOPA increases the intracellular level of dopamine, but it induces neuron cytotoxicity in a concentration-dependent manner. To investigate the molecular signaling mechanisms that underlie the concentration-dependent effects of L-DOPA on cell viability, the activities of mitogen-activated protein kinases (MAPKs) and apoptotic enzymes were measured in rat adrenal pheochromocytoma (PC12) cells in the presence of a low concentration (20 muM) and high concentrations (100-200 muM) of L-DOPA. At the low concentration, L-DOPA was not cytotoxic and its presence increased the activities of extracellular signal-regulated kinase (ERK)1/2, p38 MAPK, BadSer112, Bcl-2, and caspase-12. At the high concentrations, L-DOPA was cytotoxic and stimulated the activities of ERK1/2, p38 MAPK, c-Jun N-terminal kinase (JNK)1/2, BadSer155, caspase-12 and caspase-3. The increased levels of ERK1/2 and BadSer155 in the presence of high concentrations of L-DOPA did not protect against L-DOPA-mediated cytotoxicity. In addition, the levels of L-type Ca(2+) channel-sensitive intracellular cyclic AMP (cAMP) and Ca(2+) were elevated in the presence of L-DOPA, and the increase in the levels of intracellular cAMP may also play a role in cellular viability, since cAMP levels and cytotoxicity increased in parallel with L-DOPA concentrations and the addition of forskolin in the medium increased cytotoxicity in a concentration-dependent manner. These results suggest that, at a low and non-toxic concentration, L-DOPA may promote cell survival by increasing the activities of ERK1/2, BadSer112 and Bcl-2, while, at high concentrations, L-DOPA activates the caspase-3 cell death enzyme through the JNK1/2 and p38 MAPK signaling pathways as well as endoplasmic reticulum stress that activates caspase-12. Intracellular cAMP levels may also play a role here. The results may lead to an effective therapy for Parkinson's disease. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670675     DOI: 10.1016/j.neuroscience.2010.07.039

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Quercetin glycosides induced neuroprotection by changes in the gene expression in a cellular model of Parkinson's disease.

Authors:  Kasthuri Bai Magalingam; Ammu Radhakrishnan; Premdass Ramdas; Nagaraja Haleagrahara
Journal:  J Mol Neurosci       Date:  2014-08-17       Impact factor: 3.444

2.  Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line.

Authors:  Irmgard Paris; Patricia Muñoz; Sandro Huenchuguala; Eduardo Couve; Laurie H Sanders; John Timothy Greenamyre; Pablo Caviedes; Juan Segura-Aguilar
Journal:  Toxicol Sci       Date:  2011-04-06       Impact factor: 4.849

3.  Inhibition of DDX3 and COX-2 by forskolin and evaluation of anti-proliferative, pro-apoptotic effects on cervical cancer cells: molecular modelling and in vitro approaches.

Authors:  Doneti Ravinder; Shailima Rampogu; Gangappa Dharmapuri; Akbar Pasha; Keun Woo Lee; Smita C Pawar
Journal:  Med Oncol       Date:  2022-04-28       Impact factor: 3.064

4.  Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson's Disease.

Authors:  Bassam Felipe Mogharbel; Marco André Cardoso; Ana Carolina Irioda; Priscila Elias Ferreira Stricker; Robson Camilotti Slompo; Julia Maurer Appel; Nathalia Barth de Oliveira; Maiara Carolina Perussolo; Claudia Sayuri Saçaki; Nadia Nascimento da Rosa; Dilcele Silva Moreira Dziedzic; Christophe Travelet; Sami Halila; Redouane Borsali; Katherine Athayde Teixeira de Carvalho
Journal:  Molecules       Date:  2022-04-28       Impact factor: 4.927

5.  Oxidative stress and microglial cells in Parkinson's disease.

Authors:  Lynda J Peterson; Patrick M Flood
Journal:  Mediators Inflamm       Date:  2012-03-22       Impact factor: 4.711

6.  Maltodextrin modified liposomes for drug delivery through the blood-brain barrier.

Authors:  Zeynep Gurturk; Aysen Tezcaner; Ali Deniz Dalgic; Seval Korkmaz; Dilek Keskin
Journal:  Medchemcomm       Date:  2017-05-05       Impact factor: 3.597

7.  Impairment of neuronal mitochondrial function by L-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage.

Authors:  Philipp Hörmann; Sylvie Delcambre; Jasmin Hanke; Robert Geffers; Marcel Leist; Karsten Hiller
Journal:  Cell Death Discov       Date:  2021-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.